Israel Englander Altimmune, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Altimmune, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 100,000 shares of ALT stock, worth $364,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100,000

Previous 1,111,299 91.0%

Holding current value

$364,000

Previous $5.56 Million 93.03%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$3.5 - $7.71 $3.62 Million - $7.96 Million	-1,033,005 Reduced 92.95%	78,294 $302,000
Q1 2025 May 15, 2025	BUY	$5.0 - $7.45 $3.83 Million - $5.7 Million	765,662 Added 221.52%	1,111,299 $5.56 Million
Q4 2024 Feb 14, 2025	BUY	$6.02 - $9.85 $1.45 Million - $2.38 Million	241,484 Added 231.86%	345,637 $2.49 Million
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $499,389 - $735,463	90,798 Added 679.88%	104,153 $639,000
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $9.32 Million - $16.1 Million	-1,576,795 Reduced 99.16%	13,355 $88,000
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $11.6 Million - $19.6 Million	1,416,009 Added 813.14%	1,590,150 $16.2 Million
Q4 2023 Feb 14, 2024	SELL	$2.14 - $11.62 $1.64 Million - $8.92 Million	-767,953 Reduced 81.52%	174,141 $1.96 Million
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $436,945 - $756,106	-126,651 Reduced 11.85%	942,094 $3.33 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $3.87 Million - $15.6 Million	924,007 Added 638.4%	1,068,745 $4.51 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $3.16 Million - $5.94 Million	-360,989 Reduced 71.38%	144,738 $2.38 Million
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $3.4 Million - $7.15 Million	-318,921 Reduced 38.67%	505,727 $6.46 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $502,302 - $1.5 Million	127,488 Added 18.29%	824,648 $9.65 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $3.47 Million - $5.56 Million	588,302 Added 540.43%	697,160 $4.25 Million
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $255,451 - $366,862	-29,396 Reduced 21.26%	108,858 $997,000
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $5.01 Million - $9.99 Million	-594,488 Reduced 81.13%	138,254 $1.56 Million
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $4.52 Million - $8.64 Million	355,554 Added 94.26%	732,742 $10.4 Million
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $775,728 - $1.41 Million	98,945 Added 35.56%	377,188 $4.26 Million
Q3 2020 Nov 16, 2020	SELL	$9.93 - $33.26 $2.27 Million - $7.59 Million	-228,281 Reduced 45.07%	278,243 $3.67 Million
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $1.47 Million - $5.42 Million	506,524 New	506,524 $5.43 Million

Others Institutions Holding ALT

# of Institutions

222

Shares Held

36.5M

Call Options Held

4.92M

Put Options Held

4.18M

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $178M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account